iFAST快速药敏试验直接检测革兰阴性菌阳性血培养的多中心临床评价
该研究依据ISO 20776-2:2021在三家中心评估iFASTone快速药敏系统,直接检测阳性血培养中的肠杆菌目和非发酵革兰阴性菌,与肉汤微量稀释法比较。肠杆菌目和非发酵菌的分类一致率分别为97.8%和97.2%,敏感性与特异性均超过≥95%的接受标准,结果回报时间小于4小时。
要点
- iFAST直接 from 阳性血培养,4小时内出定性药敏结果。
- 肠杆菌目分类一致率97.8%,非发酵菌97.2%。
- 敏感性与特异性均超过≥95%的接受标准。
核心结论
- iFAST快速药敏系统直接检测阳性血培养中革兰阴性菌,与肉汤微量稀释法相比分类一致率高,敏感性和特异性均超过≥95%的接受标准。
- 结果回报时间小于4小时,支持同一班次获得药敏结果。
研究设计与样本
- 依据ISO 20776-2:2021在三家不同中心进行的首次iFASTone快速药敏系统临床研究。
- 共检测375株肠杆菌目和非发酵革兰阴性菌分离株,标本直接来自阳性血培养瓶。
- 以参考实验室肉汤微量稀释法为对照。
- 重复性评估使用12株分离株,在3个中心、每株三重复、3个不同日期、不同操作者进行。
主要发现
- 肠杆菌目的分类一致率为97.8%,非发酵革兰阴性菌为97.2%。
- 肠杆菌目的特异性和敏感性分别为98.2%和96.8%。
- 非发酵菌的特异性和敏感性分别为96.9%和98.4%。
- 重复性评估的一致率为95.7%。
关键数值与推荐
- 接受标准为敏感性和特异性均≥95%,iFAST结果超过该标准。
- 结果回报时间小于4小时。
临床怎么用
- 可用于阳性血培养中革兰阴性菌的快速药敏检测,支持同一班次获得药敏结果。
- 有助于抗菌药物管理和及时选择靶向治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: iFAST is a label-free rapid antimicrobial susceptibility test (AST) that delivers qualitative results in under 4 h from a positive blood culture bottle. The technique measures changes in the electrical properties of thousands of individual bacteria following exposure to antibiotics. We report the diagnostic accuracy from the first clinical study of the iFASTone rapid AST system in three different centers according to ISO 20776-2:2021. Compared to the reference laboratory broth microdilution method, categorical agreement was 97.8% and 97.2% for the Enterobacterales and non-fermenting gram-negative species, respectively. iFAST specificity and sensitivity for the Enterobacterales were 98.2% and 96.8%, respectively, and 96.9% and 98.4% for the non-fermenting species, exceeding the acceptance criteria (≥95% sensitivity and specificity). Reproducibility was assessed with 12 isolates across 3 sites, in triplicate, on 3 separate days, with different operators at each site. Agreement was 95.7%. IMPORTANCE: Even short delays in the initiation of antimicrobial therapy in patients with bloodstream infections are associated with increased morbidity and mortality. Consequently, current guidelines recommend initiation of empiric antimicrobial therapy within 1 h of presentation. However, empiric broad-spectrum therapy may not always be appropriate and can contribute to the selection of resistant organisms. Antimicrobial susceptibility testing (AST) is therefore critical for antimicrobial stewardship and the timely selection of targeted therapy, but conventional methods typically require 1 to 2 days to generate results. This study evaluated the diagnostic accuracy of iFAST, a new low-cost, label-free rapid AST using 375 Enterobacterales and non-fermenter isolates tested directly from positive blood cultures, according to ISO-20776-2:2021. Compared with broth microdilution, iFAST demonstrated high sensitivity, specificity, and categorical agreement, with a time to result of less than 4 h. These findings support the implementation of iFAST for same-shift AST results.
引用
- Hornsey M, Taylor I, King T, et al. Multisite clinical evaluation of the iFAST rapid antimicrobial susceptibility test direct from positive blood cultures containing gram-negative organisms. J Clin Microbiol. 2026. PMID: 42671184. doi:10.1128/jcm.00558-26
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。